# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the p...
Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $225 price target.
Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $200 price target.
2024 Financial GuidanceFull year 2024 financial guidance is reiterated as follows:Combined net product revenues for ONPATTRO, A...